Online citations, reference lists, and bibliographies.
← Back to Search

Hypoxia And Hypoxia-inducible Factor-1 Expression Enhance Osteolytic Bone Metastases Of Breast Cancer.

T. Hiraga, S. Kizaka-Kondoh, K. Hirota, M. Hiraoka, T. Yoneda
Published 2007 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Hypoxia is a common feature of solid tumors and is associated with their malignant phenotype. The transcription factor hypoxia-inducible factor-1 (HIF-1) is a major regulator of adaptation to hypoxia and is implicated in the malignant progression of cancers. Here, we studied whether hypoxia and HIF-1 expression contribute to the development of bone metastases using a well-characterized animal model of bone metastasis in MDA-MB-231 human breast cancer cells. To study the role of hypoxia in bone metastases, we tested the effects of the fusion protein (TOP3), the oxygen-dependent degradation domain of HIF-1alpha fused with HIV-TAT, and procaspase-3. TOP3 selectively induced apoptosis in hypoxic tumor cells in vitro and significantly reduced bone metastases in vivo. We next examined the role of HIF-1 in bone metastases by establishing MDA-MB-231 cells overexpressing constitutively active or dominant-negative HIF-1alpha (MDA/CA-HIF or MDA/DN-HIF, respectively). Bone metastases of MDA/CA-HIF were significantly increased with elevated number of CD31-positive blood vessels. In contrast, bone metastases were significantly reduced in MDA/DN-HIF. Because the progression of osteolytic bone metastases is due in part to the imbalance between bone formation and bone resorption, we examined the effects of hypoxia and HIF-1 on the differentiation of osteoblasts and osteoclasts. Hypoxia and CA-HIF overexpression markedly inhibited osteoblastic differentiation, whereas hypoxia increased osteoclast-like cell formation. In conclusion, these results suggest that tumor-associated hypoxia and HIF-1 expression promote the progression of bone metastases in breast cancer. Our results also suggest that hypoxia and HIF-1 lead to the development of osteolytic bone metastases by suppressing osteoblast differentiation and promoting osteoclastogenesis.
This paper references
10.1002/1097-0142(20001101)89:9<2018::AID-CNCR19>3.0.CO;2-Y
Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age
B. Movsas (2000)
10.1073/PNAS.93.3.1320
Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome.
S. Miyake (1996)
10.3892/IJO.20.2.299
The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model.
M. H. Weber (2002)
10.1038/nrc867
Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities
G. R. Mundy (2002)
10.1002/jcp.10321
Hypoxia is a major stimulator of osteoclast formation and bone resorption
T. Arnett (2003)
10.1074/JBC.M403715200
Transient Changes in Oxygen Tension Inhibit Osteogenic Differentiation and Runx2 Expression in Osteoblasts*
A. Salim (2004)
10.1007/s00774-003-0429-3
Ultrastructural and cytobiological studies on possible interactions between PTHrP-secreting tumor cells, stromal cells, and bone cells
M. Ito (2003)
Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
A. Sasaki (1998)
10.1056/NEJMOA030847
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
E. Tian (2003)
10.1016/S1534-5807(02)00369-6
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.
H. Takayanagi (2002)
10.1016/J.BBRC.2005.01.042
Hypoxic stress enhances osteoclast differentiation via increasing IGF2 production by non-osteoclastic cells.
Hayato Fukuoka (2005)
10.1093/JNCI/93.4.309
Levels of Hypoxia-Inducible Factor-1α During Breast Carcinogenesis
R. Bos (2001)
10.1002/1097-0142(20001101)89:9<2018::aid-cncr19>3.3.co;2-p
Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study.
B. Movsas (2000)
10.1073/PNAS.0406874102
Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts.
S. Komarova (2005)
10.1158/0008-5472.CAN-05-2012
Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
T. Hiraga (2006)
10.1359/jbmr.2003.18.7.1317
Metabolic Acidosis Stimulates RANKL RNA Expression in Bone Through a Cyclo‐oxygenase‐Dependent Mechanism
K. K. Frick (2003)
10.1016/S0889-5406(94)70006-0
Oxygen tension regulates osteoblast function.
O. Tuncay (1994)
Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer
増田 広 (2004)
10.1158/0008-5472.CAN-05-1891
Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
J. Dai (2005)
Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.
M. Schindl (2002)
10.1002/PROS.10193
Increased expression of bone morphogenetic protein‐7 in bone metastatic prostate cancer
H. Masuda (2003)
Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells.
H. Harada (2002)
10.1016/S0303-7207(02)00036-9
Hypoxia decreases Runx2/Cbfa1 expression in human osteoblast-like cells
J. H. Park (2002)
Hypoxiainducible factor 1a in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res 2004;6:R191–8
G Gruber (2004)
10.1038/nrc1187
Targeting HIF-1 for cancer therapy
G. Semenza (2003)
10.1182/BLOOD-2004-12-4940
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.
T. Oshima (2005)
10.1038/nature04483
Angiogenesis as a therapeutic target
N. Ferrara (2005)
10.1074/jbc.M308197200
Nitric Oxide Induces Hypoxia-inducible Factor 1 Activation That Is Dependent on MAPK and Phosphatidylinositol 3-Kinase Signaling*
K. Kasuno (2004)
10.1073/pnas.262460299
Protection against ischemic brain injury by protein therapeutics
S. Asoh (2002)
10.1074/JBC.R200030200
Hypoxia-inducible Factor and Its Biomedical Relevance*
L. E. Huang (2003)
10.1006/JSRE.2001.6128
Hypoxia regulates osteoblast gene expression.
S. Warren (2001)
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.
H. Zhong (1999)
10.1111/j.1349-7006.2003.tb01395.x
Tumor hypoxia: A target for selective cancer therapy
S. Kizaka-Kondoh (2003)
10.1046/J.1563-258X.2002.02032.X
Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications.
P. Vaupel (2002)
10.1074/JBC.M403621200
Reciprocal Roles of Msx2 in Regulation of Osteoblast and Adipocyte Differentiation*
Fumitaka Ichida (2004)
10.1126/SCIENCE.285.5433.1569
In vivo protein transduction: delivery of a biologically active protein into the mouse.
S. Schwarze (1999)
10.1186/bcr775
Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?
G. Gruber (2003)
10.1038/nrc1367
Exploiting tumour hypoxia in cancer treatment
J. M. Brown (2004)
10.1093/JNCI/95.7.516
YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.
Eun-Jin Yeo (2003)
10.1038/nrc704
Hypoxia — a key regulatory factor in tumour growth
A. Harris (2002)
10.1097/00000421-200110000-00009
Hypoxia in Human Prostate Carcinoma: An Eppendorf Po2 Study
B. Movsas (2001)
10.1161/01.RES.0000102937.50486.1B
Cell Type–Specific Regulation of Angiogenic Growth Factor Gene Expression and Induction of Angiogenesis in Nonischemic Tissue by a Constitutively Active Form of Hypoxia-Inducible Factor 1
Brian D Kelly (2003)
10.1158/0008-5472.CAN-04-4480
Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors.
S. Sobhanifar (2005)



This paper is referenced by
10.1016/j.canlet.2008.02.037
Hypoxia in microscopic tumors.
X. Li (2008)
10.1158/1078-0432.CCR-08-2417
Does Loss of CD151 Expression Promote the Metastasis of Hypoxic Colon Cancer Cells?
G. Semenza (2008)
Breast cancer cells promote osteoblastic differentiation via Sema 3A signaling pathway in vitro.
W. Shen (2015)
10.1016/j.addr.2009.01.006
The HIF-1-active microenvironment: an environmental target for cancer therapy.
S. Kizaka-Kondoh (2009)
10.1002/path.2319
Hypoxia‐inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte–osteoclast differentiation via induction of VEGF
H. Knowles (2008)
10.1177/172460081002500209
Identification of a Novel Biomarker Signature Associated with Risk for Bone Metastasis in Patients with Renal Cell Carcinoma
B. Paule (2010)
10.1089/dna.2015.3020
Inhibitors of Growth 1b Suppresses Peroxisome Proliferator-Activated Receptor-β/δ Expression Through Downregulation of Hypoxia-Inducible Factor 1α in Osteoblast Differentiation.
B. Qu (2016)
10.1158/0008-5472.CAN-07-5644
Subtypes of breast cancer show preferential site of relapse.
M. Smid (2008)
Molecular and Cellular Pathobiology CollagenProlyl HydroxylasesAreEssential for BreastCancer Metastasis
Daniele M Gilkes (2013)
10.1016/j.yexcr.2013.11.020
Tumor necrosis factor stimulates osteoclastogenesis from human bone marrow cells under hypoxic conditions.
Takayuki Nomura (2014)
10.4236/abb.2013.410A4003
Role of TGF-β in breast cancer bone metastases
A. Chiechi (2013)
10.1007/978-1-4614-0662-4_12
Role of Hypoxia-Inducible Transcription Factors in TAM Function
N. Rohwer (2011)
10.1038/nrc2540
The impact of O2 availability on human cancer
Jessica A. Bertout (2008)
10.1002/med.20224
Bone Metastases: Molecular Mechanisms and Novel Therapeutic Interventions
D. Papachristou (2012)
10.1007/s00774-010-0171-6
Inhibition of osteoclastogenesis by prolyl hydroxylase inhibitor dimethyloxallyl glycine
A. Leger (2010)
10.2174/157489208786242269
Novel Anti-Cancer Strategy in Bone Tumors by Targeting Molecular and Cellular Modulators of Bone Resorption
Brounais Benedicte (2008)
Cell Death and Survival Procollagen Lysyl Hydroxylase 2 Is Essential for Hypoxia-Induced Breast Cancer Metastasis
Daniele M Gilkes (2013)
10.1515/hsz-2012-0320
Role of hypoxia inducible factor-1α for interferon synthesis in mouse dendritic cells
Regina Wobben (2013)
10.1007/s11914-017-0378-8
Hypoxia and Bone Metastatic Disease
R. Johnson (2017)
Quantification of Changes in Vertebral Bone Quality in the Presence of Metastases
Mikhail Burke (2018)
10.1016/j.trsl.2014.12.001
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma.
E. Borsi (2015)
10.1055/s-0035-1562924
Hypoxia Potentiates LPS-Mediated Cytotoxicity of BV2 Microglial Cells In Vitro by Synergistic Effects on Glial Cytokine and Nitric Oxide System.
Daniel Frey (2015)
10.1002/path.2534
Acute hypoxia and osteoclast activity: a balance between enhanced resorption and increased apoptosis
H. Knowles (2009)
10.1016/j.bbadis.2017.08.030
MDA-MB-231 breast cancer cells fuel osteoclast metabolism and activity: A new rationale for the pathogenesis of osteolytic bone metastases.
Silvia Lemma (2017)
Effet de l'inhibition par ARN interférence de la thrombospondine-1 sur la potentialisation de la réponse immune dans un contexte tumoral
E. Marcheteau (2019)
10.5306/wjco.v5.i2.149
Bone metastases: When and how lung cancer interacts with bone.
I. Roato (2014)
10.1158/1541-7786.MCR-16-0338
Hypoxia Selectively Enhances Integrin α5β1 Receptor Expression in Breast Cancer to Promote Metastasis
Julia A Ju (2017)
10.1038/onc.2012.578
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
G. Semenza (2013)
10.1517/17425240903419608
Viral-based gene delivery and regulated gene expression for targeted cancer therapy
Y. Lu (2010)
10.1007/s12307-011-0075-6
TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases
J. Buijs (2011)
10.1074/jbc.M808348200
SEPT9_v1 Up-regulates Hypoxia-inducible Factor 1 by Preventing Its RACK1-mediated Degradation*
S. Amir (2009)
10.4161/cam.4.3.11790
Hypoxia response pathway in border cell migration
I. Djagaeva (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar